Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

LLyell Immunopharma, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
L

Lyell Immunopharma, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • History
  • Insider Transactions
Loading financials
Income statement waterfall. Revenue $4K. Net result −$44.76M. A thin axis line marks the loss-zone boundary.

Income statement waterfall. Green diagonal stripes add to the running result, red diagonal stripes subtract from it, and a thin axis line marks the loss-zone boundary.

  • Revenue: $4K. Running result $4K. Revenue: $4K.
  • Cost of revenue: $0. Running result $4K.
  • Gross profit: $4K. Running result $4K.
  • Research and development: −$39.52M. Running result −$39.52M.
  • General and administrative: −$9.58M. Running result −$49.1M.
  • Other operating (income) loss, net: −$1.76M. Running result −$50.86M.
  • Impairment of long-lived assets: $0. Running result −$50.86M.
  • Other operating benefit: $3.52M. Running result −$47.34M.
  • Operating income: −$47.34M. Running result −$47.34M.
  • Other income: $2.58M. Running result −$44.76M.
  • Pre-tax loss: −$44.76M. Running result −$44.76M.
  • Income tax benefit: $0. Running result −$44.76M.
  • Net loss: −$44.76M. Running result −$44.76M.